A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis

American Journal of Gastroenterology

Volumn 93, Issue 2, 1998, Pages 238-243

  Earnest, David L ^b   Dorsch, Ernst ^b   Jones, James ^b   Jennings, Dennis E ^b   Greski Rose, Pamela A ^a  

^a TAP Holdings Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; ESOPHAGOSCOPY; HEALING; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; ESOPHAGITIS, PEPTIC; HUMANS; OMEPRAZOLE; PROTON PUMPS;

EID: 0032008397     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.00238.x     Document Type: Article

References (20)

1. 1. Dodds WJ, Hogan WJ, Helm JF, et al. F'athogenesis of reflux esophagitis. Gastroenterology 1981;81:376-94.
2. 2. Goldberg HI, Dodds WJ, Gee S, et al. Role of acid and pepsin in acute experimental esophagitis. Gastroenterology 1969;56:223-30.
3. 3. Baldi F, Corinaldesi R, Ferrarini F, et al. Gastric secretion and emptying of liquids in reflux esophagitis. Dig Dis Sci 1981;26: 886-9.
4. 4. deCaestecker JS, Blackwell JN, Pryde A, et al. Daytime gastrooesophageal reflux is important in oesophagitis. Gut 1987;28:518-26.
5. 5. Lanzon-Miller S, Pounder RE, Hamilton MR, et al. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1987;1:239-51.
6. 6. Bell NJV, Burget DW, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(suppl 1):559-67.
7. 7. Bate CM, Kelling PWN, O'Morain C. Comparison of omeprazole and cimetidine in reflux oesophagitis: Symptomatic, endoscopic and histological evaluations. Gut 1990;31:968-72.
8. 8. Hongo M, Ohara S, Hirasawa Y, et al. Effect of lansoprazole on intragastric pH: Comparison between morning and evening dosing. Dig Dis Sci 1992;37:882-90.
9. 9. Sandmark S, Carlsson R, Fausa O, et al. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 1988;23: 625-32.
10. 10. Holt S, Howden CW. Omeprazole: Overview and opinion. Dig Dis Sci 1991;36:385-93.
11. 11. Barradell LB, Faulds D, McTavish D. Lansoprazole: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992;44:225-50.
12. 12. Kaul B, Peterson H, Ericksen H. Gastro-esophageal reflux disease: Acute and maintenance treatments with cimetidine. Scand J Gastroenterol 1986;21:139-45.
13. 2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: A controlled, double-blind study. Am J Gastroenterol 1993;88:1212-7.
14. 14. Robinson M, Sahba B, Avner D, et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995;9:25-31.
15. 15. Robinson M, Campbell DR, Sontag S, et al. Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor. Dig Dis Sci 1995;40: 590-7.
16. 16. Mulder C, Dekker W. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III, and IVA (a Dutch multicentre trial). Eur J Gastroenterol Hepatol 1996;8:1101-6.
17. 17. Pounder RE, Smith J. Drug-induced changes in plasma gastrin concentration. Gastroenterol Clin North Am 1990;19:141-53.
18. 18. Lind T, Cederberg C, Olausson M, et al. 24-hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients. Gastroenterology 1990; 99:1593-8.
19. 19. Lanzon-Miller S, Pounder RE, Hamilton MR, et al. Twenty-four-hour intragastric acidity and plasma gastrin concentration in healthy subjects and patients with duodenal or gastric ulcer or pernicious anemia. Aliment Pharmacol Ther 1987;1:225-38.
20. 20. Freston JW, Borch K, Brand SJ, et al. The effects of hypochlorhydria and hypergastrinemia on the structure and function of gastrointestinal cells: A review and analysis. Dig Dis Sci 1995;40(2 suppl):50S-62S.